Lantheus Holdings, Inc. (LNTH): M&A transaction — Lantheus closes $350M acquisition of Life Molecular Imaging; names Dr. Dinkelborg as Head of R&D

Lantheus Holdings, Inc.

Completed acquisition of Life Molecular for $350M cash after adjustments, gaining Alzheimer's PET agent Neuraceq.
Appointed Dr. Ludger Dinkelborg, former Life Molecular CEO, as Head of R&D effective Aug 1, 2025.
Transaction adds commercial infrastructure, R&D capabilities, and international footprint for Alzheimer's radiodiagnostics.
Dinkelborg will oversee Clinical Development, Regulatory Affairs, Clinical Operations, Program Management, and AI/Biomarkers.

Key facts

Extracted from this filing and checked against the source text.

M&A Transactions SEC 8-K Item 2.01/5.01 confidence 0.9

Lantheus Holdings, Inc. completed an acquisition involving Life Medical Group Limited for $350 million (closed 2025-07-21).

Action: acquisition
Counterparty: Life Medical Group Limited
Consideration: $350 million
Closing: 2025-07-21

Exact text from the filing

the Transaction pursuant to the Agreement. In accordance with the Agreement, upon the closing of the Transaction, the Purchaser paid the Seller an upfront cash payment of $350 million (following applicable purchase price adjustments under the Agreement) in exchange for all of the outstanding share capital of Life Molecular. The foregoing description of the

View on SEC.gov

Browse all m&a transactions →

Lantheus Holdings, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-162233

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.